Shanghai Henlius Biotech Inc. has announced a new partnership with FBD Biologics Limited through a license agreement. This collaboration grants Shanghai Henlius the exclusive rights to develop, manufacture, and commercialize HCB101, along with any pharmaceutical products containing it, within its designated territory. The Licensed Product is anticipated to offer new treatment options for cancer patients, enhancing the company's competitiveness in tumor treatment. The agreement marks a significant step in the research and development efforts of Shanghai Henlius, potentially enriching its product pipeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.